Every day, the kidneys filter about 50 gallons of blood, remove waste, and balance fluid levels in the human body. However, conditions like severe infections, dehydration, trauma, or surgery can cause acute kidney injury. This sudden damage affects about one in five hospitalized adults and can lead to chronic kidney disease.
A research team at Tulane University studied how kidneys restore their immune defenses after an injury occurs. The study was published in the journal Cells and focused on specialized immune cells known as macrophages. In healthy kidneys, macrophages remove dead tissue and monitor for dangerous infections.
By using a mouse model and advanced single-cell sequencing, the scientists tracked how these protective cells return after an injury. First, kidney epithelial cells send chemical signals to recruit new macrophages. As these new cells arrive, they gradually stop causing inflammation and start helping the tissue repair itself. Ultimately, this discovery could help researchers develop new treatments that prevent lasting kidney damage in patients.
Difficult words
- dehydration — a condition caused by a lack of water
- trauma — severe physical injury or damage to the body
- acute — starting quickly and becoming severe very fast
- immune — protected against a specific disease or infection
- recruit — to bring new individuals into a group or place
- inflammation — redness, swelling, and pain in damaged tissue
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Why do you think it is important for scientists to study how organs repair themselves after an injury?
- What are some healthy daily habits that people can practice to take care of their bodies?
- How can research on animals help doctors create better medical treatments for human patients?
Related articles
Affordable twice-yearly HIV injection lenacapavir to reach 120 countries
Lenacapavir, a twice-yearly HIV prevention injection, will be licensed for 120 low- and middle-income countries at US$40 a year. Rollout is expected from 2027 with funding support, but some countries and price transparency remain concerns.
Protein linked to chemotherapy resistance in ovarian cancer
Scientists found that some ovarian cancer cells survive cisplatin chemotherapy by stabilising their internal scaffold. They identified a protein that can be blocked in laboratory tests to restore the drug's effectiveness and may serve as a biomarker.
